Connext Successfully Completes Dose Escalation Part of CNT201 Phase 1/2 Clinical Trial for Dupuytren’s Contracture

– Conducted under U.S. FDA-cleared IND – Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie’s disease SEOUL, South Korea, May 7, 2025 /PRNewswire/ — Connext, a clinical stage biotechnology company, announced the successful completion of the dose escalation (Phase 1) part…